User:Umargani Jamal Mohamed M.S.Ph-d,DM

Plant as Production and Delivery Vehicles for Human Rabies Vaccines Umargani Jamal Mohamed M.S Ph-d .DM                                                                        Director Of Nuclear and Regenerative Medicine Apollo Vaccination is a great asset for eradication of infectious diseases in humans and animals. With the prevalence of antibiotic resistant bacterial strains and an alarming increase in new and re-emerging pathogens, the need for vaccination continues to be a high priority for mammalian diseases. In the last several years, a novel approach for developing improved mucosal subunit vaccines has emerged by exploiting the use of genetically modified plants. It has been demonstrated that plant-derived antigens are functionally similar to conventional vaccines and can induce neutralizing antibodies in mammalian hosts. Using genetically engineered plants for the production of immunogenic peptides also provides a new approach for the delivery of a plant-based subunit vaccine, i.e., oral delivery, provided these immunogenic peptides are expressed in an edible part of the plant, such as leaf or flower, Thus, medicinal plant can play a significant new role in promoting human health by serving as vehicles for both production and delivery of vaccines. Vaccine for rabies virus Abstract Expression of the Rabies virus (RV) fusion protein (L) gene under the control of the cauliflower mosaic virus (CaMV) 35S promoter will analyze by enzyme-linked immunosorbent assay (ELISA) in polyethylene glycol-transfect (PEG) apple leaf protoplasts. In particular, we examine whether RV-L gene expression will be enhance. By addition of a viral leader and a plant enhancer to the chimeric gene constructs. Insertion of the 5′-untranslated leader from alfalfa mosaic virus (AMV) RNA 4 between the CaMV 35S promoter and the RV-L gene increase viral expression by 5.5-fold is compared to the construct without the leader. The addition of a transcriptional enhancer from the pea plastocyanin gene (PetE) upstream of the CaMV 35S promoter to a construct containing the AMV leader further increase RV-L gene expression by 1.4-fold. Immunoblot assays shows that the RV-L will express in transfect apple protoplasts react with RV-L-monoclonal antibodies and will expect molecular mass of 68 kDa. These results demonstrate that the RV-L recombinant protein will express in an antigenic form in plant cells. Furthermore, protein expression is enhancing by modifying the transfect ion vector using both a leader and an enhancer linked to a promoter. Umargani Jamal Mohamed M.S.Ph-d,DM (talk) 15:21, 23 November 2017 (UTC)